KIT and cancer: The small molecule tyrosine kinase inhibitor imatinib depletes mast cells via blockade of the anti-apoptotic c-Kit signals necessary for cell growth and survival in vitro and in vivo [31–34]; imatinib therapy for cancer is known to cause mast cell deficiencies in treated patients [27].